

Preetesh Jain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490626/publications.pdf>

Version: 2024-02-01

156
papers

4,536
citations

117453

34
h-index

123241

61
g-index

157
all docs

157
docs citations

157
times ranked

5801
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	0.8	34
2	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (>65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
3	Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
4	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
5	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210939.	1.1	7
6	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner. <i>Current Oncology Reports</i> , 2022, 24, 1299-1311.	1.8	10
7	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. <i>Journal of Immunology</i> , 2022, 208, 2847-2855.	0.4	6
8	“Triple hit” SOX11 ^{hi} , MME ⁺ , TP53 ^{mutated} high-grade pleomorphic mantle cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 165-166.	2.0	2
9	Carcinocythemia—Cancer cell leukemia. <i>American Journal of Hematology</i> , 2021, 96, 397-398.	2.0	3
10	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. <i>British Journal of Haematology</i> , 2021, 192, e38-e42.	1.2	33
11	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	2.0	19
12	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. <i>Blood</i> , 2021, 137, 1124-1129.	0.6	7
13	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	2.0	6
14	STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2021, 12, 401-411.	0.8	4
15	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1325-1334.	0.6	4
16	A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E243-E246.	2.0	3
17	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. <i>Nature Communications</i> , 2021, 12, 2877.	5.8	35
18	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. <i>Human Pathology</i> , 2021, 118, 60-68.	1.1	4
20	Computer-aided detection of mantle cell lymphoma on F-FDG PET/CT using a deep learning convolutional neural network. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 260-270.	1.0	2
21	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	0.6	15
22	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3525-3525.	0.6	8
23	First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 445-449.	0.6	11
24	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity score-matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	1.2	7
25	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. <i>Journal of Clinical Oncology</i> , 2020, 38, 4302-4316.	0.8	22
26	Blastoid Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 941-956.	0.9	17
27	Advances in the assessment of minimal residual disease in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 127.	6.9	16
28	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 2927-2938.	2.5	61
29	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) -outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
30	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43
31	Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E232-E235.	2.0	2
32	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	1.8	57
33	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
34	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3172-3180.	0.6	2
35	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	0.7	25
36	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <i>American Journal of Hematology</i> , 2019, 94, 710-725.	2.0	151

#	ARTICLE	IF	CITATIONS
37	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	2.5	88
38	Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2035-2039.	2.5	12
39	STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. <i>Journal of Immunology</i> , 2019, 203, 3078-3085.	0.4	16
40	Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. <i>Leukemia and Lymphoma</i> , 2019, 60, 1079-1082.	0.6	3
41	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , 2019, 125, 559-574.	2.0	70
42	Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≥ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. <i>Blood</i> , 2019, 134, 3987-3987.	0.6	12
43	Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy. <i>Blood</i> , 2019, 134, 63-63.	0.6	0
44	Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2686-2691.	0.6	14
45	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	2.0	23
46	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	0.8	12
47	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
48	HyperCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
49	The absolute percent deviation of <i>IGHV</i> mutation rather than a 98% cutoff predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. <i>British Journal of Haematology</i> , 2018, 180, 33-40.	1.2	33
50	Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018, 182, 718-723.	1.2	1
51	Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As_2O_3) and all-trans retinoic acid (ATRA). <i>Blood Research</i> , 2018, 53, 169.	0.5	2
52	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. <i>British Journal of Haematology</i> , 2018, 183, 578-587.	1.2	81
53	Biclonal <i>IGHV</i> hairy cell leukemia variant and CLL successful treatment with ibrutinib and venetoclax. <i>American Journal of Hematology</i> , 2018, 93, 1568-1569.	2.0	24
54	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>British Journal of Haematology</i> , 2018, 182, 404-411.	1.2	50

#	ARTICLE	IF	CITATIONS
55	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. <i>Blood</i> , 2018, 132, 4151-4151.	0.6	4
56	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. <i>Blood</i> , 2018, 132, 1599-1599.	0.6	2
57	STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2018, 9, 21268-21280.	0.8	44
58	STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2018, 9, 33710-33718.	0.8	8
59	Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. <i>Blood</i> , 2018, 132, 1600-1600.	0.6	0
60	Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1594-1594.	0.6	0
61	Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. <i>Blood</i> , 2018, 132, 4118-4118.	0.6	0
62	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. <i>American Journal of Hematology</i> , 2017, 92, 119-120.	2.0	2
63	Constitutive Phosphorylation of STAT3 by the CK2- β -BLNK-CD5 Complex. <i>Molecular Cancer Research</i> , 2017, 15, 610-618.	1.5	18
64	Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e67-e74.	2.2	18
65	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017, 123, 2268-2273.	2.0	103
66	Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. <i>Leukemia Research</i> , 2017, 59, 105-109.	0.4	21
67	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	2.0	18
68	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
69	Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). <i>Annals of Oncology</i> , 2017, 28, 1554-1559.	0.6	44
70	Hodgkin's Lymphoma Presenting as a Cavitory Lung Mass. <i>American Journal of the Medical Sciences</i> , 2017, 354, 441.	0.4	0
71	Activation of the B cell receptor successively activates NF- κ B and STAT3 in chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2017, 141, 2076-2081.	2.3	17
72	CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lymphoma proliferation. <i>American Journal of Hematology</i> , 2017, 92, 1113-1114.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	2.0	114
74	FDG PET/CT in Malignant Eccrine Spiradenoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 125-126.	0.7	5
75	Clinical characteristics and outcomes of previously untreated patients with adult onset T-lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. <i>American Journal of Hematology</i> , 2017, 92, E595-E597.	2.0	8
76	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2154-2158.	3.2	47
77	Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. <i>American Journal of Hematology</i> , 2017, 92, 478-479.	2.0	8
78	PET-positive lymphadenopathy in CLL: Not always Richter transformation. <i>American Journal of Hematology</i> , 2017, 92, 405-406.	2.0	8
79	Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias (De novo and blast phase) Tj ETQq1 1,0,784314 rgBT /Ove 2.0 20P	2.0	20
80	A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. <i>Blood Research</i> , 2017, 52, 71.	0.5	2
81	Disseminated cytomegalovirus-associated hemophagocytic lymphohistiocytosis in an elderly patient. <i>Blood Research</i> , 2016, 51, 288.	0.5	2
82	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	2.0	88
83	Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. <i>British Journal of Haematology</i> , 2016, 174, 760-766.	1.2	76
84	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
85	Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, E478-E479.	2.0	24
86	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 616-624.	0.2	11
87	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2016, 122, 3336-3343.	2.0	14
88	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. <i>Haematologica</i> , 2016, 101, e324-e327.	1.7	5
89	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	2.0	200
90	Philadelphia-positive dimorphic blasts in mixed phenotype acute leukemia with TET2 mutation. <i>American Journal of Hematology</i> , 2016, 91, 647-648.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2016, 122, 238-248.	2.0	30
92	Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with <i>TET2</i> and <i>TP53</i> mutations. <i>American Journal of Hematology</i> , 2016, 91, 354-355.	2.0	3
93	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016, 173, 114-126.	1.2	19
94	Chronic lymphocytic leukemia (CLL) then and now. <i>American Journal of Hematology</i> , 2016, 91, 330-340.	2.0	116
95	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.2	25
96	<i>DNMT3A</i> , <i>TET2</i> , and <i>JAK2</i> mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1969-1973.	0.6	3
97	Relapsed Refractory BRAF-Negative, IGHV4-34 Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. <i>Journal of Clinical Oncology</i> , 2016, 34, e57-e60.	0.8	11
98	Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). <i>Blood</i> , 2016, 128, 2975-2975.	0.6	0
99	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 216-227.	1.3	15
100	High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. <i>American Journal of Hematology</i> , 2015, 90, 471-477.	2.0	6
101	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015, 125, 2062-2067.	0.6	303
102	Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. <i>American Journal of Hematology</i> , 2015, 90, 1091-1092.	2.0	26
103	Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 752-753.	2.0	8
104	Novel therapeutic options for relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2264-2272.	0.6	13
105	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	2.2	227
106	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	2.2	65
107	Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. <i>Molecular Cancer Research</i> , 2015, 13, 944-953.	1.5	67
108	Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. <i>Journal of Clinical Oncology</i> , 2015, 33, 1557-1563.	0.8	27

#	ARTICLE	IF	CITATIONS
109	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	2.2	86
110	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015, 56, 1643-1650.	0.6	130
111	Phase II study of methotrexate, vincristine, pegylated asparaginase, and dexamethasone (MOAD) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 120-124.	2.0	21
112	Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). <i>Blood</i> , 2015, 126, 2700-2700.	0.6	2
113	Mutated <i>NPM1</i> in patients with acute myeloid leukemia in remission and relapse. <i>Leukemia and Lymphoma</i> , 2014, 55, 1337-1344.	0.6	28
114	FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. <i>Cancer</i> , 2014, 120, 3494-3501.	2.0	6
115	Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile. <i>Leukemia and Lymphoma</i> , 2014, 55, 944-946.	0.6	0
116	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 2879-2886.	0.6	35
117	Update on the Biology and Treatment Options for Hairy Cell Leukemia. <i>Current Treatment Options in Oncology</i> , 2014, 15, 187-209.	1.3	27
118	Richter's transformation in CLL—a distinct lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 6-8.	12.5	3
119	The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. <i>Leukemia</i> , 2014, 28, 973-975.	3.3	52
120	Numb chin syndrome by precursor B acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 860-861.	2.0	9
121	Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e47-e49.	0.2	12
122	Richter's syndrome—update on biology and management. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 453-463.	0.5	4
123	Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1424-1426.	0.6	21
124	Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. <i>Current Treatment Options in Oncology</i> , 2013, 14, 127-143.	1.3	34
125	Cup-like blasts and <i>NPM1</i> and <i>FLT3</i> (ITD) mutations in acute myeloid leukemia (AML). <i>International Journal of Hematology</i> , 2013, 98, 3-3.	0.7	8
126	Recent advances in de novo CD5 ⁺ diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 798-802.	2.0	55

#	ARTICLE	IF	CITATIONS
127	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2013, 13, 169-182.	1.4	21
128	Central nervous system Richter's transformation and parvovirus B19 infection. Leukemia and Lymphoma, 2013, 54, 2070-2072.	0.6	3
129	CD4 ⁺ /CD8 ⁺ Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 610-613.	0.2	13
130	Sequential Lymphomas or Clonally Unrelated Richter Syndrome of Chronic Lymphocytic Leukemia Into Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 606-609.	0.2	1
131	Chronic Lymphocytic Leukemia With Central Nervous System Involvement: A High-Risk Disease?. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 338-341.	0.2	19
132	Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 2540-2542.	0.6	4
133	Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis. American Journal of Hematology, 2013, 88, 920-921.	2.0	1
134	Aspergillus pseudomembranous necrotizing tracheitis. American Journal of Hematology, 2013, 88, 242-242.	2.0	4
135	Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. European Journal of Haematology, 2013, 91, n/a-n/a.	1.1	4
136	Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. American Journal of Hematology, 2013, 88, 433-434.	2.0	3
137	Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica, 2013, 98, e141-e142.	1.7	7
138	Cytoplasmic globules in erythroid blasts and CLL. Blood, 2013, 121, 3305-3305.	0.6	0
139	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood, 2013, 121, 4867-4874.	0.6	124
140	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica, 2013, 98, 1686-1688.	1.7	29
141	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica, 2012, 97, 599-607.	1.7	65
142	Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood, 2012, 120, 2768-2769.	0.6	23
143	An Unusual Case of Aggressive Systemic Mastocytosis With Associated Refractory Plasma Cell Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 459-462.	0.2	6
144	Overview of recent developments in chronic lymphocytic leukemia. South Asian Journal of Cancer, 2012, 01, 84-89.	0.2	2

#	ARTICLE	IF	CITATIONS
145	Richter's transformation in chronic lymphocytic leukemia. <i>Oncology</i> , 2012, 26, 1146-52.	0.4	32
146	Advances in the Clinical Staging of Chronic Lymphocytic Leukemia. <i>Clinical Chemistry</i> , 2011, 57, 1771-1772.	1.5	8
147	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 5201-5210.	0.6	110
148	Flower cells of leukemia. <i>Blood</i> , 2010, 115, 1668-1668.	0.6	3
149	Lymphoma masquerading as acute leukemia-mystery unfolded. <i>Indian Journal of Cancer</i> , 2010, 47, 222.	0.2	0
150	Zoledronic acid induced osteonecrosis of tibia and femur. <i>Indian Journal of Cancer</i> , 2009, 46, 249.	0.2	13
151	Multiple myeloma with paraneoplastic leucocytoclastic vasculitis. <i>Indian Journal of Cancer</i> , 2009, 46, 173.	0.2	11
152	Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects. <i>Journal of Clinical Oncology</i> , 2009, 27, 7079-7079.	0.8	1
153	Rater. <i>Journal of Clinical Oncology</i> , 2009, 27, e20678-e20678.	0.8	0
154	Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer. <i>Indian Journal of Cancer</i> , 2008, 45, 83.	0.2	15
155	Newer therapeutic molecules for multiple myeloma. <i>Indian Journal of Cancer</i> , 2008, 45, 142.	0.2	1
156	Chronic myeloid leukemia presenting as paraneoplastic ocular myasthenia gravis. <i>Annals of Oncology</i> , 2007, 18, 804-805.	0.6	7